Bioengineering and Medtech against Cancer

Nanoligent has been selected to showcase at the pitch elevator session at the Bioengineering and Medtech against Cancer short course on the 25th of November. The course is organized by Medicen Paris and the Institute for Bioengineering of Catalonia (IBEC), with the collaboration of Biocat, “la Caixa” Foundation and Meditecnologia, under the framework of B·Debate. 12 selected startups and project leaders will have the chance to present their projects in front of a jury of multidisciplinary experts: industrialists, academics and investors. with an opportunity to have constructive feedback about regulatory aspects, business plan, market access and IP protection. In addition, there will also be a matchmaking opportunity with investors and key opinion leaders.

The Bioengineering and Medtech against Cancer conference is a short course that will take place in digital format the upcoming 24th and 25th of November 2020 and is part of the ToHealth program from EIT Health. It has the aim of showing the advances in the fight against cancer in the fields of nanomedicine, biophysics, mechanobiology, biotechnology, and information and communications technology.

Share the Post:

Related Posts